JP2022524018A5 - - Google Patents

Info

Publication number
JP2022524018A5
JP2022524018A5 JP2021552750A JP2021552750A JP2022524018A5 JP 2022524018 A5 JP2022524018 A5 JP 2022524018A5 JP 2021552750 A JP2021552750 A JP 2021552750A JP 2021552750 A JP2021552750 A JP 2021552750A JP 2022524018 A5 JP2022524018 A5 JP 2022524018A5
Authority
JP
Japan
Prior art keywords
fusion protein
formula
sequence
formulas
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021552750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524018A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/021498 external-priority patent/WO2020181235A1/en
Publication of JP2022524018A publication Critical patent/JP2022524018A/ja
Publication of JP2022524018A5 publication Critical patent/JP2022524018A5/ja
Priority to JP2025176328A priority Critical patent/JP2026016505A/ja
Withdrawn legal-status Critical Current

Links

JP2021552750A 2019-03-06 2020-03-06 Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法 Withdrawn JP2022524018A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025176328A JP2026016505A (ja) 2019-03-06 2025-10-20 Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962814669P 2019-03-06 2019-03-06
US62/814,669 2019-03-06
US201962899504P 2019-09-12 2019-09-12
US62/899,504 2019-09-12
US202062962332P 2020-01-17 2020-01-17
US62/962,332 2020-01-17
PCT/US2020/021498 WO2020181235A1 (en) 2019-03-06 2020-03-06 Il-10 variant molecules and methods of treating inflammatory disease and oncology

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025176328A Division JP2026016505A (ja) 2019-03-06 2025-10-20 Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法

Publications (2)

Publication Number Publication Date
JP2022524018A JP2022524018A (ja) 2022-04-27
JP2022524018A5 true JP2022524018A5 (enExample) 2023-04-26

Family

ID=72334859

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021552750A Withdrawn JP2022524018A (ja) 2019-03-06 2020-03-06 Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法
JP2025176328A Pending JP2026016505A (ja) 2019-03-06 2025-10-20 Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025176328A Pending JP2026016505A (ja) 2019-03-06 2025-10-20 Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法

Country Status (7)

Country Link
US (8) US10858412B2 (enExample)
EP (1) EP3934681A4 (enExample)
JP (2) JP2022524018A (enExample)
KR (1) KR20210139312A (enExample)
CN (2) CN121652287A (enExample)
CA (1) CA3132385A1 (enExample)
WO (1) WO2020181235A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10017739B2 (en) * 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
WO2020212598A1 (en) 2019-04-19 2020-10-22 Synerkine Pharma B.V. A fusion protein comprising il13
IL298136A (en) 2020-05-13 2023-01-01 Bonum Therapeutics Inc Preparations of protein complexes and methods of using them
CA3186753A1 (en) 2020-07-20 2022-01-27 John Mumm Dual cytokine fusion proteins comprising il-10
CN112898436A (zh) * 2020-10-23 2021-06-04 广州医科大学附属肿瘤医院 一种具有靶向功能的鼠pd1和鼠il-15基因融合蛋白的表达及其应用
KR102792982B1 (ko) * 2021-05-28 2025-04-14 한양대학교 산학협력단 세포투과성 펩티드 및 이의 용도
WO2023078245A1 (zh) * 2021-11-02 2023-05-11 广东菲鹏制药股份有限公司 Il10单体融合蛋白及其应用
WO2023114775A2 (en) * 2021-12-13 2023-06-22 Deka Biosciences, Inc. Dual cytokine fusion proteins comprising multi-subunit cytokines
US20230210953A1 (en) * 2021-12-16 2023-07-06 Deka Biosciences, Inc. Use of dual cytokine fusion proteins comprising il-10 and adoptive cell therapies or bispecific t-cell engagers to treat cancer
CA3244604A1 (en) 2022-02-22 2023-08-31 Deka Biosciences, Inc. METHOD FOR REDUCING A BISPECIFIC T LYMPHOCYTE RECRUITER OR A CHIMERICAL ANTIGEN RECEPTOR T LYMPHOCYTE CYTOKINE RELEASE SYNDROME USING INTERLEUKIN 4 OR 10, OR AN ASSOCIATED FUSION PROTEIN
CN114632156B (zh) * 2022-05-17 2022-08-16 中国人民解放军军事科学院军事医学研究院 Tim-3在预防、治疗或减轻疼痛中的应用
WO2024097875A1 (en) * 2022-11-02 2024-05-10 Shattuck Labs, Inc. Fusion proteins for the treatment of nonalcoholic steatohepatitis
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法
WO2025110822A1 (ko) * 2023-11-24 2025-05-30 주식회사 메드팩토 피브로넥틴 엑스트라도메인 b (extradomain b of fibronectin, edb-fn) 및 전환성장인자 베타(transforming growth factor β, tgfβ)에 특이적으로 결합하는 융합 단백질 및 이의 용도
CN121108363A (zh) * 2024-06-12 2025-12-12 广东菲鹏制药股份有限公司 一种融合蛋白及其用途
CN119613546B (zh) * 2025-02-10 2025-05-13 细胞生态海河实验室 Il-10抗体及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2648484A1 (en) * 2006-05-08 2007-11-15 Philogen Spa Antibody-targeted cytokines for therapy
CN101868246A (zh) * 2007-09-21 2010-10-20 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
DK3281952T3 (da) * 2007-10-30 2020-08-03 Philogen Spa Antigen, der er forbundet med reumatoid artritis
NO2344540T3 (enExample) * 2008-10-02 2018-04-28
WO2012045334A1 (en) * 2010-10-05 2012-04-12 Synthon Bv Biologically active il-10 fusion proteins
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
PE20150645A1 (es) 2012-08-08 2015-05-11 Roche Glycart Ag Proteinas de fusion de interleuquina 10 y usos de las mismas
ES2743423T3 (es) * 2012-10-03 2020-02-19 Philogen Spa Conjugado de anticuerpos para su uso en el tratamiento de una enfermedad inflamatoria intestinal
PE20151893A1 (es) 2013-03-14 2015-12-30 Parkash Gill Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular
WO2015117930A1 (en) * 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukine 10 immunoconjugates
CN104403004B (zh) * 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
AU2015364396B2 (en) * 2014-12-19 2018-08-09 Alkermes, Inc. Single chain Fc fusion proteins
WO2017091611A1 (en) * 2015-11-23 2017-06-01 Immungene, Inc Enhanced cancer immunotherapy using antibody-interferon fusion molecules
RU2018124307A (ru) * 2015-12-04 2020-01-14 Новартис Аг Антительно-цитокиновые привитые композиции и способы применения для иммунорегуляции

Similar Documents

Publication Publication Date Title
JP2022524018A5 (enExample)
JP2023534847A5 (enExample)
IL300062A (en) Dual fused cytokine proteins containing IL-10
RU2451689C2 (ru) Новые антипролиферативные антитела
Both et al. Monoclonal antibodies for prophylactic and therapeutic use against viral infections
JP2024546938A5 (enExample)
US8486663B2 (en) Compositions and methods for generating antibodies
JP7164528B2 (ja) Ｐｄ－１に特異的に結合する可能な抗体及びその機能的断片
JP2021516976A5 (enExample)
IL313525A (en) Dual cytokine fusion proteins containing multisubunit cytokines
US20150175700A1 (en) Polyclonal bispecific antibody compositions and method of use
JP2022512915A5 (enExample)
Roselli et al. CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms: E. Roselli et al.
KR950016781A (ko) 면역접합체
JP2022033734A (ja) グルタミンシンセターゼ遺伝子内相補ベクターを用いた高レベルのヘテロマータンパク質発現細胞の直接選択
RU2016126488A (ru) Иммунотерапия рака
JP2018518200A (ja) 多重特異性抗体プラットフォームおよびその関連方法
JP2024537804A5 (enExample)
JP2025508882A5 (enExample)
JP2022527994A (ja) 三重特異性結合性タンパク質、方法、およびその使用
JP2024546999A5 (enExample)
JP2024515263A (ja) 改善された特性を有する二機能性分子のための新規足場構造
JP2025503109A5 (enExample)
JP2022512540A5 (enExample)
Glassy Production methods for generating human monoclonal antibodies